Literature DB >> 14646477

Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin.

L Cartee1, G L Kucera, M C Willingham.   

Abstract

A variety of chemotherapeutic agents induce cell death via apoptosis. We had shown previously that gemcitabine (2',2'-difluorodeoxycytidine) induced an atypical apoptosis in BG-1 human ovarian cancer cells; therefore, further studies were conducted to characterize more precisely gemcitabine-induced apoptosis in BG-1 cells compared to a general inducer of apoptosis, staurosporine. BG-1 cells exposed to 0.5, 1.0 and 10 microM gemcitabine for 8 h, or staurosporine (1.0 microM) for 6 h, exhibited high molecular weight DNA fragmentation (50 kbp); however, only staurosporine treatment produced internucleosomal DNA fragments (200 bp) in a laddered pattern on the agarose gel. Staurosporine (1.0 microM) rapidly induced phosphatidylserine plasma membrane translocation that increased linearly with time as measured by annexin V-FITC binding, and similar kinetics were observed for caspase activation by staurosporine in BG-1 cells. In contrast, 10 microM gemcitabine increased phosphatidylserine expression in a small fraction of cells (5-10%) vs. untreated controls over the course of 48 h and significant caspase activity was detected within 12 h of drug exposure. Time-lapse video microscopy of BG-1 cells exposed to 1.0 microM staurosporine or 10 microM gemcitabine for up to 72 h showed that the morphologic changes and kinetics of cell death induced by these agents differed significantly. We also evaluated the apoptosis induced by paclitaxel (a mitotic poison) and cisplatin (an agent not dependent on cell cycle functions) in BG-1 cells by these methods because these drugs are used clinically to treat ovarian cancer. Our findings demonstrate that the kinetics of apoptotic cell death induced by gemcitabine and other chemotherapeutic agents should be taken into account when designing treatment strategies for ovarian cancer.

Entities:  

Year:  1998        PMID: 14646477     DOI: 10.1023/a:1009614703977

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  4 in total

1.  Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.

Authors:  Chandra Bartholomeusz; Fumiyuki Yamasaki; Hitomi Saso; Kaoru Kurisu; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  J Cancer       Date:  2011-08-07       Impact factor: 4.207

2.  A linear programming computational framework integrates phosphor-proteomics and prior knowledge to predict drug efficacy.

Authors:  Zhiwei Ji; Bing Wang; Ke Yan; Ligang Dong; Guanmin Meng; Lei Shi
Journal:  BMC Syst Biol       Date:  2017-12-21

3.  ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.

Authors:  Erhong Meng; Aparna Mitra; Kaushlendra Tripathi; Michael A Finan; Jennifer Scalici; Steve McClellan; Luciana Madeira da Silva; Eddie Reed; Lalita A Shevde; Komaraiah Palle; Rodney P Rocconi
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

4.  In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model.

Authors:  Eleni Kolokotroni; Dimitra Dionysiou; Christian Veith; Yoo-Jin Kim; Jörg Sabczynski; Astrid Franz; Aleksandar Grgic; Jan Palm; Rainer M Bohle; Georgios Stamatakos
Journal:  PLoS Comput Biol       Date:  2016-09-22       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.